ImmuCell (NASDAQ:ICCC) Stock Passes Above 50-Day Moving Average – Should You Sell?

ImmuCell Corporation (NASDAQ:ICCC) crossed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $9.55 and traded as high as $10.60. ImmuCell shares last traded at $10.34, with a volume of 37,793 shares traded.

Analyst Ratings Changes

Several analysts have commented on the company. Wall Street Zen upgraded ImmuCell to a “strong-buy” rating in a report on Saturday, June 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of ImmuCell in a report on Thursday, July 2nd. One analyst has rated the stock with a Sell rating, According to MarketBeat, ImmuCell has a consensus rating of “Sell”.

ImmuCell Trading Up 7.7%

The company has a debt-to-equity ratio of 0.24, a quick ratio of 2.60 and a current ratio of 4.82. The firm has a market capitalization of $103.62 million, a price-to-earnings ratio of -190.80 and a beta of 0.56. The business has a fifty day moving average price of $9.66 and a 200 day moving average price of $7.66.

ImmuCell (NASDAQ:ICCC) last issued its earnings results on Thursday, May 14th. The biotechnology company reported $0.21 earnings per share for the quarter, beating analysts’ consensus estimates of $0.05 by $0.16. The firm had revenue of $10.36 million for the quarter, compared to analysts’ expectations of $5.40 million. ImmuCell had a negative return on equity of 1.88% and a negative net margin of 1.82%.

Insider Buying and Selling at ImmuCell

In other news, CEO Boekhorst Paul Francis Oliv Te acquired 8,000 shares of ImmuCell stock in a transaction dated Thursday, June 18th. The shares were acquired at an average cost of $9.49 per share, with a total value of $75,920.00. Following the purchase, the chief executive officer directly owned 17,785 shares of the company’s stock, valued at approximately $168,779.65. This trade represents a 81.76% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 5.70% of the stock is owned by corporate insiders.

Institutional Trading of ImmuCell

Institutional investors and hedge funds have recently bought and sold shares of the business. Dimensional Fund Advisors LP lifted its holdings in shares of ImmuCell by 3.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 56,030 shares of the biotechnology company’s stock valued at $355,000 after acquiring an additional 1,749 shares in the last quarter. Geode Capital Management LLC boosted its position in ImmuCell by 4.2% during the 2nd quarter. Geode Capital Management LLC now owns 71,852 shares of the biotechnology company’s stock worth $500,000 after purchasing an additional 2,907 shares during the period. Militia Capital Management LLC acquired a new stake in ImmuCell in the 1st quarter valued at $114,000. Mesirow Financial Investment Management Inc. increased its holdings in ImmuCell by 199.6% in the 4th quarter. Mesirow Financial Investment Management Inc. now owns 36,481 shares of the biotechnology company’s stock valued at $224,000 after purchasing an additional 24,303 shares in the last quarter. Finally, Steadtrust LLC raised its position in ImmuCell by 79.1% in the fourth quarter. Steadtrust LLC now owns 56,770 shares of the biotechnology company’s stock valued at $349,000 after purchasing an additional 25,070 shares during the period. Institutional investors and hedge funds own 13.47% of the company’s stock.

About ImmuCell

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.